BCRX
BIOCRYST PHARMACEUTICALS INC
Latest close $9.02 as of Aug 4, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 4 parsed filing(s) · 1 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| State Street CIK0000093751 | Mar 31, 2026 observed May 12, 2026 filed · 42d Initial Schedule 13G | Initial Schedule 13G | 12.2M +1.1M | 12.00% 0.00 pts | $9.52 | $8.80 | $9.02 |
| State Street CIK0000093751 | Dec 31, 2025 observed Feb 9, 2026 filed · 40d Initial Schedule 13G | Initial Schedule 13G | 11.1M | 12.00% | $7.80 | $6.30 | $9.02 |
| BlackRock Legacy CIK0001364742 | Aug 31, 2024 observed Sep 10, 2024 filed · 10d Schedule 13G amendment | Reported accumulation | 21.0M +2.4M | 10.20% +1.10 pts | $7.72 | $9.02 |